PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced
NAR Cancer · 02.04.2025 · 7 (2)
DOI: 10.1093/narcan/zcaf015 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, online erschienen am 23.04.2025. Verfasst von Kaveri Goel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL 35294, United States. Hauptthemen laut MEDLINE: X-ray Repair Cross Complementing Protein 1, Poly(ADP-ribose) Polymerase Inhibitors, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, Department of Defense.
Abstract (Originalsprache)
Prostate cancer (PCa) is the second most common cancer worldwide and the fifth leading cause of cancer-related deaths among men. The emergence of metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) exemplifies the complex disease management for PCa. PARP inhibitors (PARPis) are being tested to treat mCRPC in tumors with defective homologous recombination repair (HRR) to address this complexity. However, increasing resistance towards PARPi in HRR-deficient patients and the low percentage of HRR-defective mCRPC patients requires the identification of new genes whose deficiency can be exploited for PARPi treatment. XRCC1 is a DNA repair protein critical in the base excision repair (BER) and single strand break repair (SSBR) pathways. We analyzed PCa patients’ cohorts and found that XRCC1 expression varies widely, with many patients showing low XRCC1 expression. We created XRCC1 deficiency in PCa models to examine PARPi sensitivity. XRCC1 loss conferred hypersensitivity to PARPi by promoting the accumulation of DNA double-strand breaks, increasing cell-cycle arrest, and inducing apoptosis. We confirmed that XRCC1 expression correlated with PARPi sensitivity using a doxycycline-inducible system. Therefore, we conclude that XRCC1 expression level predicts response to PARPi, and the clinical utility of PARPi in PCa can extend to low XRCC1 expressing tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL 35294, United States.
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, United States.
- Division of Preventive Medicine, The University of Alabama at Birmingham, Birmingham, AL 35294, United States.
ORCID-Profile: Natalie R Gassman
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- Department of Defense
- Morehouse School of Medicine
- Univerity of Alabama Cancer Center
- Center for AIDS Research
- Comprehensive Cancer Center
Zitieren
APA
Goel, K., Venkatappa, V., Krieger, K. L., Chen, D., Sreekumar, A., & Gassman, N. R. (2025). PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced. NAR Cancer, 7(2). https://doi.org/10.1093/narcan/zcaf015
Vancouver
Goel K, Venkatappa V, Krieger KL, Chen D, Sreekumar A, Gassman NR. PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced. NAR Cancer. 2025;7(2). doi:10.1093/narcan/zcaf015
BibTeX
@article{Goel2025,
author = {Goel, Kaveri and Venkatappa, Vani and Krieger, Kimiko L and Chen, Dongquan and Sreekumar, Arun and Gassman, Natalie R},
title = {PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced},
journal = {NAR Cancer},
year = {2025},
volume = {7},
number = {2},
doi = {10.1093/narcan/zcaf015}
}
EUVIMED